IQVIA downgraded by Jefferies with a new price target
$IQV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Jefferies downgraded IQVIA from Buy to Hold and set a new price target of $242.00 from $266.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/4/2024 | $275.00 | Outperform | RBC Capital Mkts |
| 7/24/2024 | $266.00 → $242.00 | Buy → Hold | Jefferies |
| 6/6/2024 | $270.00 | Buy | Goldman |
| 2/26/2024 | $290.00 | Outperform | Leerink Partners |
| 2/15/2024 | Buy → Neutral | Guggenheim | |
| 2/13/2024 | $285.00 | Buy | BTIG Research |
| 11/2/2023 | $248.00 → $202.00 | Outperform → Neutral | Robert W. Baird |
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
Jefferies analyst David Windley downgrades IQVIA Hldgs (NYSE:IQV) from Buy to Hold and lowers the price target from $266 to $242.
During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:IQV), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 6 3 0 0 Last 30D 2 3 1 0 0 1M Ago 0 2 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 1 0 0 Analysts have set 12-month price targets for IQVIA Hldgs, revealing an average target of $265.62, a high estimate of $300.00, and a low estimate of $230.00. This upward trend is evident, with the current average reflecting a
Morgan Stanley analyst Tejas Savant maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and raises the price target from $270 to $280.
Redburn Atlantic initiated coverage of IQVIA with a rating of Buy
RBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $275.00
Jefferies downgraded IQVIA from Buy to Hold and set a new price target of $242.00 from $266.00 previously
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intellige
Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati